Verge Genomics Begins Patient Dosing In Phase 1 Trial Of Vrg50635 A Novel Therapeutic For Als
Verge Genomics, A Clinical-Stage, Tech-Enabled Biotechnology Company, Announced That The First Subject Has Been Dosed In A Phase 1 Clinical Trial Of Vrg50635. Vrg50635 Is A Small Molecule Inhibitor Of Pikfyve, A Novel Therapeutic Target For Amyotrophic Lateral Sclerosis (Als) Discovered By Converge, Verge
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!